A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
Recruiting in Palo Alto (17 mi)
+3 other locations
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: Jacobio Pharmaceuticals Co., Ltd.
No Placebo Group
Trial Summary
What is the purpose of this trial?This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.
Eligibility Criteria
Participant Groups
1Treatment groups
Experimental Treatment
Group I: JAB-3068 (SHP2 inhibitor)Experimental Treatment1 Intervention
Daily oral administration of JAB-3068
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
The University of Texas M. D. Anderson Cancer CenterHouston, TX
HealthONE Clinic Services Oncology-HematologyDenver, CO
Florida Cancer SpecialistsSarasota, FL
Sarah Cannon Research InstituteNashville, TN
Loading ...
Who is running the clinical trial?
Jacobio Pharmaceuticals Co., Ltd.Lead Sponsor